Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ard.2003.014043v1
63/11/1413    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bruynesteyn, K
Right arrow Articles by van der Heijde, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruynesteyn, K
Right arrow Articles by van der Heijde, D
Annals of the Rheumatic Diseases 2004;63:1413-1418
© 2004 by BMJ Publishing Group Ltd & European League Against Rheumatism


EXTENDED REPORT

Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months’ follow up

K Bruynesteyn , R Landewé , Sj van der Linden , D van der Heijde

Department of Internal Medicine, Division of Rheumatology, University of Maastricht, Maastricht, The Netherlands

Correspondence to:
Correspondence to:
Professor D van der Heijde
Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands; dhe{at}sint.azm.nl

Objectives: To investigate whether plain radiographs can show changes in joint damage due to rheumatoid arthritis (RA) within 3 months.

Methods: 188 film pairs taken with a 3 month interval were evaluated. They were scored with (chronological) and without (paired) knowledge of the sequence of the films according to the Sharp/van der Heijde method. Changes in joint damage were analysed on a group and an individual level for different subsets of patients. Sample sizes required to detect statistically and clinically significant differences were estimated based on the percentages of patients with progression larger than the smallest detectable change (SDC).

Results: Changes in joint damage were seen by both the chronological and the paired scoring method. The percentage of patients with progression of joint damage larger than the corresponding SDCs (1.7 and 2.4) varied in the subsets from 18% to 64% if based on the chronological change-scores and from 9% to 36% using paired change-scores. Acceptable sample size estimates were seen in several subsets, depending on (a) how the investigated drug would reduce the individual risk of progression of joint damage (by an absolute or a relative risk reduction model); (b) how damage was scored (chronological or paired); (c) the baseline risk; and (d) whether a two sided or one sided test would be used.

Conclusions: Changes in joint damage due to RA can be detected reliably already within 3 months. This finding can be used to plan short term, randomised controlled trials with radiographic progression as primary outcome.


Abbreviations: ARR, absolute risk reduction; DAS28, modified disease activity score; DMARD, disease modifying antirheumatic drug; IQR, interquartile range; RA, rheumatoid arthritis; RRR, relative risk reduction; SDC, smallest detectable change

Keywords: rheumatoid arthritis; radiography; joint damage




This article has been cited by other articles:


Home page
Ann Rheum DisHome page
B Combe, R Landewe, C Lukas, H D Bolosiu, F Breedveld, M Dougados, P Emery, G Ferraccioli, J M W Hazes, L Klareskog, et al.
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Ann Rheum Dis, January 1, 2007; 66(1): 34 - 45.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D Baeten, J Houbiers, E Kruithof, B Vandooren, F Van den Bosch, A M Boots, E M Veys, A M M Miltenburg, and F De Keyser
Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis
Ann Rheum Dis, August 1, 2006; 65(8): 990 - 997.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
R Landewe and D van der Heijde
Presentation and analysis of radiographic data in clinical trials and observational studies
Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv48 - iv51.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 BMJ Publishing Group Ltd & European League Against Rheumatism